扩大CHD2-相关脑病变的突变格局和临床表型
Angela Clara-Hwang1, Stefani Stefani1, Tracy Lau1
1From the Department of Neuromuscular Disorders (A.C.-H., T.L., B.A., R.K., R.M., S.E., H.H.); Department of Clinical and Experimental Epilepsy (A.C.-H.), UCL Queen Square Institute of Neurology; The Francis Crick Institute (A.C.-H.), London, United Kingdom; Cyprus Paediatric Neurology Institute (S.S., P.N.), Nicosia, Cyprus; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (M. Scala, P.S.), Università Degli Studi di Genova; U.O.C. Genetica Medica (M. Scala, F.Z.), IRCCS Istituto Giannina Gaslini, Genoa, Italy; Department of Neurosciences, Pediatric Psychiatry and Neurology (P.B.), Santobono-Pausilipon Children's Hospital, Naples, Italy; Medical Genetics Unit (F.M.), IRCCS Istituto Giannina Gaslini, Genoa, Italy; Department of Paediatric Neurology (S.B.), Tbilisi State Medical University, GA; Department of Pediatric Neurology (V.M.S., V.G.), Indira Gandhi Institute of Child Health, Bangalore, India; MediClub Hospital (U.G.), Baku, Azerbaijan; Department of Clinical and Functional Neurology (A.M., A.-L.P., C.B., D.M.V.), University Hospital of Lyon, Pierre-Bénite, France; Division of Pediatric Neurology (A.G., H.P.), Department of Pediatrics, Faculty of Medicine, Erciyes University, Kayseri, Turkey; Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (J. de Bellescize), University Hospitals of Lyon; Pediatric and Fetal Imaging Department (S.C.), Femme-Mere-Enfant Hospital, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, France; Department of Neuropediatrics (A.W.), Jena University Hospital, Jena, Germany; MVZ Mitteldeutscher Praxisverbund Humangenetik GmbH (A.S.), Johannesstr. 147, Erfurt, Germany; Pediatric Neurology Unit (A.R.-P.), Pediatrics Department, Hospital Universitari Germans Trias I Pujol, Universitat Autonoma de Barcelona, Spain; Department of Genetics (N.C., G.L.), Hospices Civils de Lyon, France; NeuroMyoGene Institute (N.C., G.L.), CNRS UMR 5261-INSERM U1315, Claude Bernard Lyon 1 University, France; Hunter Genetics (H.G.), Waratah, NSW 2298, Australia; University of Newcastle, Callaghan, NSW 2308, Australia; John Hunter Children's Hospital (J. Brown), Australia; Institute of Medical Genetics (T.F., K.S., A.R.), University of Zurich, Zurich, Switzerland; (A.R.), University Children's Hospital Zurich; University of Zurich Research Priority Program ITINERARE: Innovative Therapies in Rare Diseases, AdaBD: Adaptive Brain Circuits in Development and Learning, Switzerland; Neuroradiology Unit (M. Severino.), IRCCS Giannina Gaslini Institute, Genoa, Italy; University of Nicosia Medical School (P.N.), Nicosia, Cyprus.
这项研究在患有严重发育性和性脑病变的患者中发现了新的CHD2基因变异. 这些发现扩大了对不同人群中CHD2相关疾病的理解.
科学领域:
- 遗传学 遗传学 是一个
- 神经科学是一个神经科学.
- 分子生物学分子生物学
背景情况:
- CHD2基因编码了一种参与染色质重塑的蛋白质.
- 病原性CHD2变异与早期发育性和性脑病变,耐药性和神经发育障碍有关.
- 全球超过225名被诊断的患者表现出多种CHD2等位基变异.
研究的目的:
- 在患有遗传性和发育性脑病变的患者中报告新的CHD2变异.
- 描述具有新的CHD2变体的个体的分子和临床特征.
- 扩大对代表性不足的人群中CHD2相关表型的理解.
主要方法:
- 对来自17个家庭的17个个人的案例系列分析.
- 新型致病性或可能致病性CHD2变体的分子特征.
- 临床评估包括神经发育,神经和神经精神特征,以及神经成像.
主要成果:
- 确定了17个具有新型致病性/可能致病性CHD2变异的个体.
- 所有人都出现了严重的全球发育迟缓和童年发作的肌细胞性.
- 共同特征包括神经精神问题 (自闭症,多动症),运动障碍,低血压/高血压,以及特定的神经成像发现,如下层虫子低血压等.
结论:
- 这一案例系列突出了新的CHD2变体,并扩大了已知的表型谱.
- 这些发现强调了CHD2基因测试在早期发作的脑病变中的重要性.
- 这项研究有助于了解全球不同人口中CHD2疾病的患病率和特征.


